Ponatinix Ponatinib 45 mg

Ponatinix (Ponatinib) 45 MG

Ponatinib

Price: $690.00

Ponatinib prevent serious or life-threatening blood clots in your legs or lungs, heart attacks, or strokes. If you have a blood clot in your lungs or legs; a stroke; high blood pressure; hyperlipidemia (high levels of cholesterol in your blood); a slow, fast, or irregular heartbeat; peripheral vascular disease (narrowing of blood vessels in feet, legs, or arms causing numbness, pain, or coldness in that part of the body); a heart attack; or heart disease. Else, experience any of the following symptoms like, call your doctor immediately: chest pain; shortness of breath; dizziness or fainting; sudden confusion or trouble speaking or understanding; sudden numbness or weakness of face, arm, or leg on one side of the body; sudden severe headache; leg, arm, back, neck, or jaw pain; feeling of warmth in the lower leg; or swelling of the feet, ankles, or lower legs.

whatsapp
Whatsapp +8801922101029
wechat
Wechat +8801922101029
Categories: , Tags: ,

Description

Ponatinix (Ponatinib), generic is a prescription Tablets use to treat of blood cancer which is chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) medicines are received. Ponatinix manufactured by Beacon Pharma Ltd. in Bangladesh.

Indications

Ponatinib is a kinase inhibitor indicated for the:

Adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.

Patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Pharmacology Ponatinib

Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively. In vitro, activity of additional kinases with IC 50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. There is viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduce the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.

Dosage & Administration Ponatinib

Recommended dose: 45 mg taken orally once daily with or without food

Hepatic Impairment: 30 mg orally once daily. Modify or interrupt dosing for hematologic and non-hematologic toxicity.

Side Effects

The most common non-hematologic adverse reactions (≥20%) were, abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity.

Pregnancy & Lactation

 In animals, it cause fetal harm when administered to a pregnant woman. There are no available data on Ponatinib use in pregnant women. In animal reproduction studies, oral administration of ponatinib to pregnant rats during organogenesis caused adverse developmental effects. At doses lower than human exposures at the recommended human dose. Advise pregnant women of the potential risk to a fetus.

There is no data on the presence of ponatinib in human milk. The effects on the breastfed infant or on milk production.

Use in Special Populations

Pediatric Use: Safety and effectiveness not to establish in pediatric patients.

Storage Conditions

Store Ponatinib at room temperature between 20° C to 25° C.

 

For any inquiries please contact us

For more Oncology medicine, visit our SHOP

No images in this gallery yet!